Australian biopharmaceutical company Immuron (ASX:IMC) has submitted a response letter to the US FDA in response to its clinical hold on trials of the new oral therapeutic targeting campylobacter. …
Latest Video
New Stories
-
HBF reports revenue growth with expanding membership outside WA
September 25, 2023 - - Other Health -
US FDA grants conditional approval to the brand name of Dimerix's DMX-200
September 25, 2023 - - Australian Biotech -
Budget outcome confirms double-digit growth for pharmaceutical spend
September 25, 2023 - - Latest News -
These major processes related to public health programs can not continue in this way
September 25, 2023 - - Latest News -
Hospital pharmacy launches new professional recognition program
September 25, 2023 - - Latest News -
The 'Week in Review' Podcast - 22 September
September 22, 2023 - - Podcast -
National and Labour commit to addressing Pharmac's fiscal 'cliff'
September 22, 2023 - - Latest News